Alnylam Pharmaceuticals Financial Statements (ALNY)
|
|
|
|
Report date
|
|
|
13.02.2020 |
11.02.2021 |
10.02.2022 |
23.02.2023 |
15.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
219.8 |
492.9 |
844.3 |
1 037 |
1 828 |
|
2 095 |
|
Operating Income, bln rub |
|
|
-939.4 |
-828.4 |
-708.7 |
-785.1 |
-282.2 |
|
-188.1 |
|
EBITDA, bln rub |
? |
|
-868.1 |
-736.3 |
-661.6 |
-926.6 |
-258.2 |
|
-130.9 |
|
Net profit, bln rub |
? |
|
-886.1 |
-858.3 |
-852.8 |
-1 131 |
-440.2 |
|
-332.3 |
|
|
OCF, bln rub |
? |
|
-278.4 |
-615.0 |
-641.7 |
-541.3 |
104.2 |
|
56.6 |
|
CAPEX, bln rub |
? |
|
140.2 |
70.4 |
76.4 |
72.1 |
62.2 |
|
40.5 |
|
FCF, bln rub |
? |
|
-418.6 |
-685.3 |
-718.1 |
-613.3 |
41.9 |
|
16.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 134 |
1 243 |
1 413 |
1 654 |
1 800 |
|
1 977 |
|
Cost of production, bln rub |
|
|
25.1 |
78.1 |
140.1 |
168.8 |
310.4 |
|
306.4 |
|
R&D, bln rub |
|
|
655.1 |
654.8 |
792.2 |
883.0 |
1 004 |
|
1 098 |
|
Interest expenses, bln rub |
|
|
0.000 |
84.5 |
143.0 |
156.0 |
121.2 |
|
134.2 |
|
|
Assets, bln rub |
|
|
2 395 |
3 407 |
3 643 |
3 546 |
3 830 |
|
4 205 |
|
Net Assets, bln rub |
? |
|
1 439 |
1 016 |
588.2 |
-158.2 |
-220.6 |
|
32.4 |
|
Debt, bln rub |
|
|
303.8 |
521.2 |
997.6 |
1 320 |
2 683 |
|
1 302 |
|
Cash, bln rub |
|
|
1 536 |
1 874 |
2 436 |
2 192 |
2 439 |
|
2 772 |
|
Net debt, bln rub |
|
|
-1 232 |
-1 353 |
-1 438 |
-872.2 |
243.2 |
|
-1 470 |
|
|
Ordinary share price, rub |
|
|
115.2 |
130.0 |
169.6 |
237.7 |
191.4 |
|
161.5 |
|
Number of ordinary shares, mln |
|
|
109.3 |
115.0 |
118.5 |
121.7 |
124.9 |
|
128.6 |
|
|
Market cap, bln rub |
|
|
12 584 |
14 945 |
20 087 |
28 919 |
23 908 |
|
20 772 |
|
EV, bln rub |
? |
|
11 352 |
13 592 |
18 649 |
28 047 |
24 152 |
|
19 302 |
|
Book value, bln rub |
|
|
1 439 |
1 016 |
588 |
-423 |
-918 |
|
32 |
|
|
EPS, rub |
? |
|
-8.11 |
-7.46 |
-7.20 |
-9.30 |
-3.52 |
|
-2.58 |
|
FCF/share, rub |
|
|
-3.83 |
-5.96 |
-6.06 |
-5.04 |
0.34 |
|
0.12 |
|
BV/share, rub |
|
|
13.2 |
8.84 |
4.97 |
-3.47 |
-7.35 |
|
0.25 |
|
|
EBITDA margin, % |
? |
|
-395.0% |
-149.4% |
-78.4% |
-89.3% |
-14.1% |
|
-6.25% |
|
Net margin, % |
? |
|
-403.2% |
-174.1% |
-101.0% |
-109.0% |
-24.1% |
|
-15.9% |
|
FCF yield, % |
? |
|
-3.33% |
-4.59% |
-3.57% |
-2.12% |
0.18% |
|
0.08% |
|
ROE, % |
? |
|
-61.6% |
-84.5% |
-145.0% |
714.9% |
199.5% |
|
-1 027% |
|
ROA, % |
? |
|
-37.0% |
-25.2% |
-23.4% |
-31.9% |
-11.5% |
|
-7.90% |
|
|
P/E |
? |
|
-14.2 |
-17.4 |
-23.6 |
-25.6 |
-54.3 |
|
-62.5 |
|
P/FCF |
|
|
-30.1 |
-21.8 |
-28.0 |
-47.2 |
570.0 |
|
1 293 |
|
P/S |
? |
|
57.3 |
30.3 |
23.8 |
27.9 |
13.1 |
|
9.92 |
|
P/BV |
? |
|
8.75 |
14.7 |
34.1 |
-68.4 |
-26.0 |
|
642.0 |
|
EV/EBITDA |
? |
|
-13.1 |
-18.5 |
-28.2 |
-30.3 |
-93.5 |
|
-147.5 |
|
Debt/EBITDA |
|
|
1.42 |
1.84 |
2.17 |
0.94 |
-0.94 |
|
11.2 |
|
|
R&D/CAPEX, % |
|
|
467.4% |
930.7% |
1 037% |
1 225% |
1 615% |
|
2 712% |
|
|
CAPEX/Revenue, % |
|
|
63.8% |
14.3% |
9.05% |
6.95% |
3.40% |
|
1.93% |
|
| Alnylam Pharmaceuticals shareholders |
